Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.
2.

The economic burden of depression and the cost-effectiveness of treatment.

Wang PS, Simon G, Kessler RC.

Int J Methods Psychiatr Res. 2003;12(1):22-33. Review.

PMID:
12830307
3.

Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model.

Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ.

CNS Drugs. 2007;21(4):319-34. Erratum in: CNS Drugs. 2006;21(5):405.

PMID:
17381185
4.

Cost-effectiveness of interventions for depressed Latinos.

Schoenbaum M, Miranda J, Sherbourne C, Duan N, Wells K.

J Ment Health Policy Econ. 2004 Jun;7(2):69-76.

PMID:
15208467
5.
6.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
7.

Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.

Bereza BG, Machado M, Einarson TR.

Clin Ther. 2009 Jun;31(6):1279-308. doi: 10.1016/j.clinthera.2009.06.004. Review.

PMID:
19695395
8.

A review of the health-related quality of life and economic impact of Parkinson's disease.

Dowding CH, Shenton CL, Salek SS.

Drugs Aging. 2006;23(9):693-721. Review.

PMID:
17020395
9.

Are psychological treatments for depression in primary care cost-effective?

Bosmans JE, van Schaik DJ, de Bruijne MC, van Hout HP, van Marwijk HW, van Tulder MW, Stalman WA.

J Ment Health Policy Econ. 2008 Mar;11(1):3-15. Review.

PMID:
18424872
10.

Cost-effectiveness of group psychotherapy for depression in Uganda.

Siskind D, Baingana F, Kim J.

J Ment Health Policy Econ. 2008 Sep;11(3):127-33.

PMID:
18806302
11.

The burden of schizophrenia on caregivers: a review.

Awad AG, Voruganti LN.

Pharmacoeconomics. 2008;26(2):149-62. Review.

PMID:
18198934
12.
14.
15.

Social and economic burden of mood disorders.

Simon GE.

Biol Psychiatry. 2003 Aug 1;54(3):208-15. Review.

PMID:
12893097
16.

Evidence of cost-effective treatments for depression: a systematic review.

Barrett B, Byford S, Knapp M.

J Affect Disord. 2005 Jan;84(1):1-13. Review.

PMID:
15620380
17.

Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.

O'Connor AB.

Pharmacoeconomics. 2009;27(2):95-112. doi: 10.2165/00019053-200927020-00002. Review.

PMID:
19254044
18.

The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis.

McLoughlin DM, Mogg A, Eranti S, Pluck G, Purvis R, Edwards D, Landau S, Brown R, Rabe-Heskith S, Howard R, Philpot M, Rothwell J, Romeo R, Knapp M.

Health Technol Assess. 2007 Jul;11(24):1-54.

19.

The economic burden of depression in the US: societal and patient perspectives.

Greenberg PE, Birnbaum HG.

Expert Opin Pharmacother. 2005 Mar;6(3):369-76. Review.

PMID:
15794728
20.

Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

Brouwer WB, Koopmanschap MA, Rutten FF.

Health Econ. 1997 May-Jun;6(3):253-9.

PMID:
9226143

Supplemental Content

Support Center